Xeris Pharmaceuticals Reports Preliminary 2025 Revenue Milestone
05.02.2026 - 07:53:05
Xeris Pharmaceuticals has announced preliminary financial results for the 2025 fiscal year that surpassed its own guidance. The company's strong commercial performance, marked by a 44% surge in revenue and consistently positive adjusted EBITDA, sets the stage for its next phase of clinical development. A key question for investors is whether this operational momentum can sustainably fund the expansion of its research pipeline.
Beyond its marketed products, Xeris is progressing its clinical development candidates. A significant milestone was reached with XP-8121, an investigational treatment for hypothyroidism. The company has confirmed the injectable, once-weekly therapy is now ready to enter Phase 3 clinical trials.
This candidate received a boost in December when the United States Patent and Trademark Office granted a key patent application. The awarded patent protection strengthens the potential market position for XP-8121, which targets a substantial patient population.
Should investors sell immediately? Or is it worth buying Xeris Pharmaceuticals?
Profitability Provides Foundation for Growth
The preliminary figures highlight a year of robust portfolio growth. For the full year 2025, Xeris anticipates total revenue of approximately $292 million, exceeding its previous forecast. The fourth quarter was particularly dynamic, driven largely by the drug Recorlev. Sales of Recorlev are estimated to have reached $45 million, representing a 22% increase over the third quarter.
Operational profitability has been a cornerstone of the biopharma firm's stability. Xeris achieved a positive adjusted EBITDA in every single quarter of 2025. This consistent performance indicates that the commercial portfolio—comprising Gvoke, Keveyis, and Recorlev—is generating a solid financial base to support the broader corporate strategy.
Final Audited Results and Outlook Ahead
Xeris Pharmaceuticals will release its complete, audited financial statements for the fourth quarter and full year 2025 on Monday, March 2, 2026. Management will host a conference call at 6:30 p.m. CET to discuss the operational results in detail. The call is also expected to provide a specific timeline for the Phase 3 clinical study of XP-8121.
Ad
Xeris Pharmaceuticals Stock: Buy or Sell?! New Xeris Pharmaceuticals Analysis from February 5 delivers the answer:
The latest Xeris Pharmaceuticals figures speak for themselves: Urgent action needed for Xeris Pharmaceuticals investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 5.
Xeris Pharmaceuticals: Buy or sell? Read more here...
